NEOGENOMICS INC
About NEOGENOMICS INC
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2018
- $131.2M
- Net income
- -$108.0M
- Total assets
- $1.4B
- Market cap
- $1.4B
- Gross margin
- 43.2%
- Operating margin
- -15.9%
- Net margin
- -14.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $727.3M
- Cost of revenue
- $413.0M
- Gross profit
- $314.3M
- Operating expenses
- $430.2M
- Operating income
- -$115.9M
- Income tax
- -$2.2M
- Net income
- -$108.0M
Balance sheet
- Total assets
- $1.4B
- Current assets
- $376.3M
- Total liabilities
- $523.3M
- Current liabilities
- $88.3M
- Shareholders’ equity
- $836.6M
Cash flow
- Operating cash flow
- $5.2M
- Investing cash flow
- -$12.3M
- Financing cash flow
- -$200.3M
- Net cash flow
- -$207.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.4B
- Shares outstanding
- 129.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 25, 1996
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $108.0M in FY2018.
- Revenue grew 50% from FY2021 to FY2025.
- Gross margin of 43.2%, net margin -14.9%.
- Trading 17% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NEOGENOMICS INC.
Write a review
News about NEOGENOMICS INC
News & sentiment via Polygon.io
